Get more info on this report!Worldwide Market for Prescription Dermatological Drugs, 7th Editi...
This transition will play a role in the future development of the dermatological industryover the forecast period. The glo...
•   Synthetic Lipids for Skin Healing: pseudoceramides that are involved in skin cell       growth could be used in treati...
•   Roche Group (F. Hoffmann-La Roche Ltd.)   •   Schering (now Merck)-Plough Corporation   •   Sinclair Pharma Plc.   •  ...
Bioavailability    Drug Delivery Methods    Demographics of Skin Disorders, Incidence, and PrevalenceCHAPTER THREE: ISSUES...
Description of Products    Benzoyl Peroxide    Description of Products    Current Suppliers    Retinoids    Topical Formul...
Retinoids    Sunscreens    Other Agents    Research and Development    Market Size and Growth    Global Market    Markets ...
Future of the Market    Competitive AnalysisCHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS    Overview    Description of Pro...
Future of the Market    Competitive AnalysisCHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS    Overview    De...
Japan    Rest of World    The Future of the Market    Competitive AnalysisCHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS    Ove...
Market Size and Growth    Global Market by Type    Markets by Geographical Region    United States    Europe    Japan    R...
United States    Europe    Japan    Rest of World    The Future of the Market    Competitive AnalysisCHAPTER TWELVE: MISCE...
Competitive AnalysisCHAPTER THIRTEEN: WORLD MARKET SUMMARY    Overview    Total Market Size and Forecast    Market and Com...
SkinMedica      Stiefel Laboratories, Inc      Valeant Pharmaceuticals, IncAPPENDIX: Company DirectoryTABLE OF EXHIBITSCHA...
Figure 4-4: The Global Market for Prescription Antiacne and Rosacea Drugs    Revenues by Geographical Region 2001-2011    ...
Figure 5-6: The Global Market for Antiaging and Photodamage Drugs Share by      Geographical Region 2011      Table 5-10: ...
Table 7-2: Common Prescription Topical Antifungal Dermatological Drugs      Table 7-3: Prescription Antifungal Dermatologi...
Table 8-4: The Global Market for Prescription Hair Loss and Hair Removal Drugs      Revenues by Geographical Region 2001-2...
Table 10-3: The Global Market for Prescription Psoriasis Drugs by Type 2001-     2011     Figure 10-1: The Global Market f...
Figure 11-4: The Global Market for Prescription Skin Cancer Drugs Share by      Geographical Region 2011      Table 11-12:...
Figure 13-3: The Global Market for Dermatological Drugs Market Share by Type       2011       Table 13-3: Global Market fo...
Upcoming SlideShare
Loading in …5
×

Worldwide Market for Prescription Dermatological Drugs, 7th Edition, The

481 views

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total views
481
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
6
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Worldwide Market for Prescription Dermatological Drugs, 7th Edition, The

  1. 1.    Get more info on this report!Worldwide Market for Prescription Dermatological Drugs, 7th Edition, TheApril 1, 2010This Kalorama Information report, Worldwide Market for Prescription DermatologicalDrugs details the various categories of prescription dermatological drugs, describes theglobal market and identifies major market factors that may help to shape the market fortreatments in the future.Full Coverage of Nine Prescription Dermatological Drug SegmentsThe global market for prescription dermatology drugs includes products in the followingcategories: • Prescription Acne and Rosacea Drugs (Benzoyl, Retinoids, Antibiotics, Other) • Prescription Antiaging and Photodamage Drugs (Keratolytics, Moisturizers, Retinoids, Sun-screens, Other Agents) • Prescription Dermatitis and Seborrhea Drugs(Topical, Systemic, Others) • Prescription Fungal Infection Drugs (Topical, Systemic) • Prescription Hair Loss and Hair Removal Drugs(Antiandrogens, Androgen Inhibitors, Others) • Prescription Hyperpigmentation/Melasma Drugs(Hyperpigmentation/Melasma Agents, Depigmenting Agents) • Prescription Psoriasis Drugs (Topical, Systemic, Other) • Prescription Skin Cancer Drugs • Other Prescription Skin Disorder Drugs(Antiviral Drugs, Antiparasitic Agents)A Shift to Cosmetic MedicationsThe pharmaceutical industry is facing a tougher environment in general, due to harderregulations for gaining approvals for mainstream products, economic issues, and adwindling pipeline of new products. Reliance on blockbuster drugs is all but over,causing a shift of focus for many drug research and development entities. By focusingon cosmetic medications, many manufacturers are realizing less scrutiny from the FDAand a growing need in the niche markets such as dermatology.
  2. 2. This transition will play a role in the future development of the dermatological industryover the forecast period. The global pharmaceutical sector has little choice but tocontinue expanding through mergers and acquisitions for some time to come.A Look at Key Trends in DermatologicsIt’s a very dynamic time for the prescription dermatological drug industry. Consolidation,economic times, new technologies and genetic discoveries are among the trends thatthe industry is seeing, and these are among those analyzed in this report: • Economic Downturn: The prescription dermatological drug industry was not immune to the recent economic downturn. Some product categories fared better than others, and these areas are detailed in the report. • Cosmetic Dermatologists: The report discusses the debate over a new function for dermatologists in cosmetic procedures. • Patient Compliance: Drugs are only effective if patients comply with dosage and time of administration. This is an increasing concern for dermatologists and the industry. • Melanoma Survival Rates Falter: While some other cancers have declined in incidence, melanoma remains a growing problem, and new dermatological aids will be in demand. • Phosphatidylglycerol and Psoriasis: Researchers now understand more about this lipid and how it may affect psoriasis. • New Itch Gene Found: One of many genetic discoveries in the dermatological field recently, the GRPR discovery could have clinical implications soon. • New Filler Options: Collagen has been used for twenty years; now two new filler products are being developed and more could be on the way. • Consumer Confusion: This is a highly competitive market. With information overload on product choices, its up to the industry to educate. • Genetic Link to Psoriasis: Discovery of a possible block to the pathway that activates T cells could change treatment. • Rx-to-OTC Switches: Several dermatological products that were prescription are now available OTC. • Cosmeceuticals: New personal care products, incorporating antioxidants and polypeptides, go beyond topical moisturizers and anti-wrinkle creams will be a factor in this market. • Teledermatology: The taking of and sending of digital pictures for consultation has changed medical practice in this specialty. • Reimbursement Issues: The coverage of dermatological drugs can vary be limited. • Laser Therapy: While no replacement for prescription dermatological drugs, these technologies may compliment dermatological treatment. • Narrowband Ultraviolet B: A new treatment option for actinic prurigo, solar urticaria and cutaneous porphyria has recently become available. • Photodynamic Therapy: A possible replacement for surgical excision of primary skin cancer.
  3. 3. • Synthetic Lipids for Skin Healing: pseudoceramides that are involved in skin cell growth could be used in treating skin diseases in which skin cells grow abnormally • Importance of Drug Delivery: Microdermabrasion and novel electrophoretic products are among the delivery systems that could be seen in future products. • New Oral Medications for Acne: extended release minocycline, pre-treatment antibiotics and other drugs are an option. • Industry Consolidation:The last couple of years has seen a huge consolidation effort going in the pharmaceutical industry. Many top pharmaceutical companies face a deficit in their pipelines and the U.S. Food and Drug Administration is taking a more conservative approach in approving new medicines • PYCR1 gene: Scientists may have discovered a link between this gene and skin aging. This discovery could open the door for new discoveries in pharmaceuticals that could mediate the protein in individuals with the gene mutation.The information and analysis presented in this report are based on extensive interviewswith senior management of top companies in the dermatology market. Backgroundinformation was obtained from a comprehensive search of published literature andreports obtained from various government, business, medical trade, and internationaljournals. Key information from published literature was used to conduct interviews withover 42 industry executives and product managers to validate and obtain expert opinionon current and future trends in the dermatological market. Interviews were also used toconfirm and/or adjust market size estimates, as well as in formulating marketprojections.The following companies are profiled in this report: • Allergan Inc. • Allergan Inamed Corporation • Barrier Therapeutics, Inc • Bayer AG • PharmaDerm Pharmaceuticals, Inc • Bristol-Myers Squibb • Collagenex (now Galderma) Pharmaceuticals • Galderma S.A. • Genentech, Inc. • GlaxoSmithKline Plc • Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho-McNeil) • Medicis Pharmaceutical Corporation • Merck & Company, Inc. • Mylan Pharmaceuticals, Inc, • Novartis Pharmaceuticals Corporation • Nycomed Inc. • Pfizer, Inc. • Q-Med AB
  4. 4. • Roche Group (F. Hoffmann-La Roche Ltd.) • Schering (now Merck)-Plough Corporation • Sinclair Pharma Plc. • SkinMedica • Stiefel Laboratories, Inc. • Valeant Pharmaceuticals, Inc.All market data pertains to the global market at the manufacturers’ level. Data areexpressed in current U.S. dollars. The base year for data was 2009. Historical data areprovided for each of the years 2007 to 2009, and forecast data are provided for each ofthe years 2009 through 2014. Historical, base year, and forecast data are provided foreach market segment. Market shares are provided for each market segment for the2009 base year.Table of ContentsCHAPTER ONE: EXECUTIVE SUMMARY Introduction Scope and Methodology Size and Growth of the Market Issues and Trends Affecting Market Competitor AnalysisCHAPTER TWO: INTRODUCTION Structure and Function of the Skin Epidermis Dermis Subcutaneous Tissue Epidermal Appendages Functions of the Skin Effects of Aging on the Skin Dermatological Conditions and Treatment Pharmacokinetics Drug Absorption Distribution
  5. 5. Bioavailability Drug Delivery Methods Demographics of Skin Disorders, Incidence, and PrevalenceCHAPTER THREE: ISSUES AND TRENDS Patient Compliance Cosmetic Dermatologists Melanoma Survival Rates Falter Phosphatidylglycerol and Psoriasis New Itch Gene Found New Filler Options Consumer Confusion Genetic Link to Psoriasis Biologic Dermatology Rx-to-OTC Switches Cosmeceuticals Antioxidants Polypeptides Teledermatology Reimbursement Issues Accutane IPledge Program Laser Therapy Narrowband Ultraviolet B Photodynamic Therapy New Oral Medications and Research for Acne Synthetic Lipids for Skin Healing Importance of Drug DeliveryCHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS Description of Disorders
  6. 6. Description of Products Benzoyl Peroxide Description of Products Current Suppliers Retinoids Topical Formulations Systemic Formulations Current Suppliers Antibiotics Description of Products Current Suppliers Oral Contraceptives Research and Development Market Size and Growth Global Market Markets by Geographical Region United States Europe Japan Rest of World The Future of the Market Competitive AnalysisCHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS Overview Description of Products Keratolytics Moisturizers
  7. 7. Retinoids Sunscreens Other Agents Research and Development Market Size and Growth Global Market Markets by Geographical Region United States Europe Japan Rest of World The Future of the Market Competitive AnalysisCHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS Overview Description of Products Topical Corticosteroids Systemic Corticosteroids Other Products Research and Development Market Size and Growth Global Market by Type Markets by Geographical Region United States Europe Japan Rest of World
  8. 8. Future of the Market Competitive AnalysisCHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS Overview Description of Products Systemic Formulations Terbinafine Itraconazole Fluconazole Griseofulvin Ketoconazole Current Suppliers Topical Formulations Polyenes Azoles Allylamines and Benzylamines Other Topical Formulations New Products Current Suppliers Research and Development Market Size and Growth Global Market by Type Markets by Geographical Region United States Europe Japan Rest of World
  9. 9. Future of the Market Competitive AnalysisCHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS Overview Description of Products Antiandrogens Androgen Inhibitors Oral Contraceptives Other Treatments Research and Development Market Size and Growth Global Market by Type Markets by Geographical Region United States Europe Japan Rest of World Future of the Market Competitive AnalysisCHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION / MELASMA DRUGS Overview Description of Products Research and Development Market Size and Growth Global Market Markets by Geographical Region United States Europe
  10. 10. Japan Rest of World The Future of the Market Competitive AnalysisCHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS Overview Description of Products Topical Psoriasis Products Anthralin Coal Tar Methoxsalen Second-generation Retinoids Tazarotene Topical Vitamin D Vitamin D Analogs Vanos Systemic Psoriasis Preparations Betamethasone Cortisone Acetate Cyclosporine Hydrocortisone Methotrexate Olopatadine Hydrochloride Tacrolimus Light Therapy Biologics Research and Development
  11. 11. Market Size and Growth Global Market by Type Markets by Geographical Region United States Europe Japan Rest of World Future of the Market Competitive AnalysisCHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS Overview Nonmelanoma Skin Cancers Actinic Keratoses Basal Cell Carcinoma Squamous Cell Carcinoma Cutaneous T-cell Lymphoma Dysplastic Nevus Syndrome Malignant Melanoma Description of Products 5-Fluorouracil Mechlorethamine/Nitrogen Mustard Carmustine/BCNU (Topical) Vinblastine (Intralesional) and Others Research and Development Market Size and Growth Global Market Markets by Geographical Region
  12. 12. United States Europe Japan Rest of World The Future of the Market Competitive AnalysisCHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS—ANTIVIRALSAND ANTIPARASITICS Overview Antivirals Antiparasitics Description of Products Topical Antivirals Antiviral Drugs Immunoenhancing Drugs Current Suppliers Antiparasitic Agents Current Suppliers Other Skin Related Products Research and Development Market Size and Growth Global Market Markets by Geographical Region United States Europe Japan Rest of World The Future of the Market
  13. 13. Competitive AnalysisCHAPTER THIRTEEN: WORLD MARKET SUMMARY Overview Total Market Size and Forecast Market and Competitive AnalysisCHAPTER FOURTEEN: CORPORATE PROFILES Allergan Inc Allergan Inamed Corporation Barrier Therapeutics, Inc Bayer AG PharmaDerm Pharmaceuticals, Inc Bristol-Myers Squibb Collagenex (now Galderma) Pharmaceuticals Galderma S.A Genentech, Inc GlaxoSmithKline Plc Johnson & Johnson (Janssen Pharmaceutica, Ortho Dermatological, Ortho- McNeil) Medicis Pharmaceutical Corporation Merck & Company, Inc Mylan Pharmaceuticals, Inc, Novartis Pharmaceuticals Corporation Nycomed Inc Pfizer, Inc Q-Med AB Roche Group (F. Hoffmann-La Roche Ltd.) Schering (now Merck)-Plough Corporation Sinclair Pharma Plc
  14. 14. SkinMedica Stiefel Laboratories, Inc Valeant Pharmaceuticals, IncAPPENDIX: Company DirectoryTABLE OF EXHIBITSCHAPTER ONE: EXECUTIVE SUMMARY Table 1-1: The Global Market for Prescription Dermatological Drugs 2001, 2006, and 2011 Figure 1-1: The Global Market for Prescription Dermatological Drugs 2001, 2006, and 2011CHAPTER TWO: INTRODUCTION Table 2-2: Worldwide Incidence and Prevalence of Selected Dermatologic Conditions Chapter three: Issues and Trends Table 3-1: Selected Dermatological Rx-to-OTC SwitchesCHAPTER FOUR: PRESCRIPTION ANTIACNE AND ROSACEA DRUGS Table 4-1: Common Benzoyl Peroxide Formulations Table 4-2: Common Retinoid Formulations Table 4-3: Common Antibiotic Formulations Table 4-4: Common Oral Contraceptive Formulations Table 4-5: Prescription Acne, Actinic Keratosis and Rosacea Formulations in Development Table 4-6: The Global Market for Prescription Acne and Rosacea Drugs by Type 2001-2011 Figure 4-1: The Global Market for Prescription Acne and Rosacea Drug Revenues by Type, 2001-2011 70 Figure 4-2: The Global Market for Prescription Acne and Rosacea Drugs Share by Type 2006 Figure 4-3: The Global Market for Prescription Acne and Rosacea Drugs Share by Type 2011 Table 4-7: The Global Market for Prescription Antiacne and Rosacea Drugs by Geographical Region 2001-2011
  15. 15. Figure 4-4: The Global Market for Prescription Antiacne and Rosacea Drugs Revenues by Geographical Region 2001-2011 Figure 4-5: The Global Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2006 Figure 4-6: The Global Market for Prescription Antiacne and Rosacea Drugs Share by Geographical Region 2011 Table 4-8: Global Market for Prescription Antiacne and Rosacea Drugs Revenues and Market Share by Supplier 2006 Figure 4-7: Global Market for Acne and Rosacea Drugs Market Share by Leading Supplier 2006CHAPTER FIVE: PRESCRIPTION ANTIAGING AND PHOTODAMAGE DRUGS Table 5-1: Common Prescription Keratolytic Formulations Table 5-2: Occlusive Moisturizers—Categories of Ingredients Table 5-3: Common Prescription Moisturizers Table 5-4: Common Prescription Retinoids for Antiaging and Photodamage Table 5-5: Common Prescription Sunscreens Table 5-6: Other Prescription Antiaging and Photodamage Products Table 5-7: Prescription Antiaging and Photodamage Formulations in Development Table 5-8: The Global Market Antiaging and Photodamage Drugs by Type 2001- 2011 Figure 5-1: The Global Market for Antiaging and Photodamage Drugs Revenues by Type 2001-2011 Figure 5-2: The Global Market for Antiaging and Photodamage Drugs Share by Type 2006 Figure 5-3: The Global Market for Antiaging and Photodamage Drugs Share by Type 2011 Table 5-9: The Global Market for Prescription Antiaging and Photodamage |Drugs by Geographical Region 2001-2011 Figure 5-4: The Global Market for Prescription Antiaging and Photodamage Drugs, Revenues by Geographical Region 2001-2011 Figure 5-5: The Global Market for Antiaging and Photodamage Drugs Share by Geographical Region 2006
  16. 16. Figure 5-6: The Global Market for Antiaging and Photodamage Drugs Share by Geographical Region 2011 Table 5-10: Global Market for Prescription Antiaging and Photodamage Drugs Revenues and Market Share by Supplier 2006 Figure 5-7: Global Market for Prescription Antiaging and Photodamage Drugs, Market Share by Leading Supplier 2006CHAPTER SIX: PRESCRIPTION DERMATITIS AND SEBORRHEA DRUGS Table 6-1: Common Prescription Topical Corticosteroid Preparations Table 6-2 Common Prescription Systemic Corticosteroids Table 6-3: Prescription Other Dermatitis Formulations Table 6-4: Prescription Dermatitis Formulations in Development Table 6-5: The Global Market for Prescription Dermatitis and Seborrhea Drugs by Type 2001-2011 Figure 6-1: The Global Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Type 2001-2011 Figure 6-2: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2006 Figure 6-3: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Type 2011 Table 6-6: The Global Market for Prescription Dermatitis and Seborrhea Drugs by Geographical Region 2001-2011 Figure 6-4: The Global Market for Prescription Dermatitis and Seborrhea Drugs Revenues by Geographical Region 2001-2011 Figure 6-5: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2006 Figure 6-6: The Global Market for Prescription Dermatitis and Seborrhea Drugs Share by Geographical Region 2011 Table 6-7: Global Market for Prescription Dermatitis and Seborrhea Drugs Revenues and Market Share by Supplier 2006 Figure 6-7: Global Market for Prescription Dermatitis and Seborrhea Drugs Market Share by Leading Supplier 2006CHAPTER SEVEN: PRESCRIPTION ANTIFUNGAL DRUGS Table 7-1: Common Prescription Systemic Antifungal Dermatological Formulations
  17. 17. Table 7-2: Common Prescription Topical Antifungal Dermatological Drugs Table 7-3: Prescription Antifungal Dermatological Drugs in Development Table 7-4: The Global Market for Prescription Antifungal Dermatological Drugs by Type 2001-2011 152 Figure 7-1: The Global Market for Prescription Antifungal Dermatological Drugs Revenues by Type 2001-2010 Figure 7-2: The Global Market for Prescription Antifungal Dermatological Drugs Share by Type 2006 154 Figure 7-3: The Global Market for Prescription Antifungal Dermatological Drugs, Share by Type 2011 Table 7-5: The Global Market for Prescription Antifungal Dermatological Drugs by Geographical Region 2001-2011 Figure 7-4: The Global Market for Prescription Antifungal Dermatological Drugs Revenues by Geographical Region 2001-2011 Figure 7-5: The Global Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2006 Figure 7-6: The Global Market for Prescription Antifungal Dermatological Drugs, Share by Geographical Region 2011 Table 7-6: Global Market for Prescription Antifungal Dermatological Drugs Revenues and Market Share by Supplier 2006 Figure 7-7: Global Market for Prescription Antifungal Dermatological Drugs Market Share by Leading Supplier 2006CHAPTER EIGHT: PRESCRIPTION HAIR LOSS AND HAIR REMOVAL DRUGS Table 8-1: Common Prescription Hair Loss or Hair Removal Formulations Table 8-2: Prescription Hair Loss or Hair Removal Formulations in Development 170 Table 8-3: The Global Market for Prescription Hair Loss and Hair Removal Drugs by Type 2001-2011 Figure 8-1: The Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Type 2001-2011 Figure 8-2: The Global Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2006 Figure 8-3: The Global Market for Prescription Hair Loss and Hair Removal Drugs, Share by Type 2011
  18. 18. Table 8-4: The Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Geographical Region 2001-2011 Figure 8-4: The Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues by Geographical Region 2001-2011 Figure 8-5: The Global Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2006 Figure 8-6: The Global Market for Prescription Hair Loss and Hair Removal Drugs Share by Geographical Region 2011 Table 8-5: Global Market for Prescription Hair Loss and Hair Removal Drugs Revenues and Market Share by Supplier 2006 Figure 8-7: Global Market for Prescription Hair Loss and Hair Removal Drugs Market Share by Leading Supplier 2006CHAPTER NINE: PRESCRIPTION HYPERPIGMENTATION/MELASMA DRUGS Table 9-1: Common Prescription Hyperpigmentation/Melasma Formulations Table 9-2: Common Prescription Depigmenting Agents Table 9-3: The Global Market for Hyperpigmentation/Melasma Drugs by Type 2001-2011 Figure 9-1: The Global Market for Hyperpigmentation/Melasma Drugs Revenues by Type 2001-2011 Figure 9-2: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs, Share by Type 2006 Figure 9-3: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs Share by Type 2011 Table 9-4: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs by Geographical Region 2001-2011 Figure 9-4: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs Revenues by Geographical Region 2001-2011 Figure 9-5: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs, Share by Geographical Region 2006 Figure 9-6: The Global Market for Prescription Hyperpigmentation/ Melasma Drugs, Share by Geographical Region 2011CHAPTER TEN: PRESCRIPTION PSORIASIS DRUGS Table 10-1: Common Prescription Psoriasis Preparations Table 10-2: Prescription Psoriasis Preparations in Development
  19. 19. Table 10-3: The Global Market for Prescription Psoriasis Drugs by Type 2001- 2011 Figure 10-1: The Global Market for Prescription Psoriasis Drugs Revenues by Type 2001-2011 Figure 10-2: The Global Market for Prescription Psoriasis Drugs Share by Type 2006 Figure 10-3: The Global Market for Prescription Psoriasis Drugs Share by Type 2011 Table 10-4: The Global Market for Prescription Psoriasis Drugs by Geographical Region 2001-2011 227 Figure 10-4:The Global Market for Prescription Psoriasis Drugs Revenues by Geographical Region 2001-2011 Figure 10-5: The Global Market for Prescription Psoriasis Drugs Share by Geographical Region 2006 Figure 10-6: The Global Market for Prescription Psoriasis Drugs Share by Geographical Region 2011 Table 10-5: Global Market for Prescription Psoriasis Drugs Revenues and Market Share by Supplier 2006 231 Figure 10-7: Global Market for Prescription Psoriasis Drugs Market Share by Leading Supplier 2006 231CHAPTER ELEVEN: PRESCRIPTION SKIN CANCER DRUGS Table 11-1: Malignant Conditions of the Skin Table 11-2: Common Prescription Topical and Intralesional Chemotherapeutic Agents Table 11-3: Prescription Skin Cancer Preparations in Development Table 11-4: The Global Market for Skin Cancer Drugs 2001-2011 Figure 11-1: The Global Market for Skin Cancer Drugs 2001-2011 Table 11-5: The Global Market for Prescription Skin Cancer Drugs by Geographical Region 2001-2011 247 Figure 11-2: The Global Market for Prescription Skin Cancer Drugs Revenues by Geographical Region 2001-2011 Figure 11-3: The Global Market for Prescription Skin Cancer Drugs Share by Geographical Region 2006
  20. 20. Figure 11-4: The Global Market for Prescription Skin Cancer Drugs Share by Geographical Region 2011 Table 11-12: Global Market for Prescription Skin Cancer Drugs Revenues and Market Share by Supplier 2006 Figure 11-5: Global Market for Skin Cancer Drugs Market Share by Leading Supplier 2006CHAPTER TWELVE: MISCELLANEOUS SKIN DISORDER DRUGS --ANTIVIRALSAND ANTIPARASITICS Table 12-1: Common Prescription Topical Antiviral Formulations Table 12-2: Common Prescription Topical Antiparasitic Formulations Table 12-3: Prescription Miscellaneous Skin Preparations in Development Table 12-4: The Global Market for Prescription Miscellaneous Skin Disorder Drugs by Type 2001-2011 Figure 12-1: The Global Market for Miscellaneous Skin Disorder Drugs | Revenues by Type 2001-2011 Figure 12-2: The Global Market for Miscellaneous Skin Disorder Drugs Share by Type 2006 Figure 12-3: The Global Market for Miscellaneous Skin Disorder Drugs Share by Type 2011 Table 12-6: The Global Market for Prescription Miscellaneous Drugs by Geographical Region 2001-2011 268 Figure 12-4: The Global Market for Prescription Miscellaneous Drugs Revenues by Geographical Region 2001-2011 Figure 12-5: The Global Market for Prescription Miscellaneous Drugs .. Share by Geographical Region 2006 Figure 12-6: The Global Market for Prescription Miscellaneous Drugs Share by Geographical Region 2011CHAPTER THIRTEEN: WORLD MARKET SUMMARY Table 13-1: The Global Market for Prescription Dermatological Drugs, Revenues by Segment, 2001-2011 Figure 13-1: The Global Market for Prescription Dermatological Drugs Revenues by Dermatological Segment 2001-2011 Figure 13-2: The Global Market for Dermatological Drugs Market Share by Type 2006
  21. 21. Figure 13-3: The Global Market for Dermatological Drugs Market Share by Type 2011 Table 13-3: Global Market for Prescription Dermatological Drugs Revenues and Segments of Participation by Leading Market Participants 2006Available immediately for Online Download athttp://www.marketresearch.com/product/display.asp?productid=2616119   US: 800.298.5699UK +44.207.256.3920Intl: +1.240.747.3093Fax: 240.747.3004 

×